Scarica l'app Stockscreener
0.621
1.32%
-0.0083
Precedente Chiudi:
$0.6293
Aprire:
$0.64
Volume 24 ore:
140.54K
Relative Volume:
0.43
Capitalizzazione di mercato:
$24.60M
Reddito:
-
Utile/perdita netta:
$-17.78M
Rapporto P/E:
-1.1307
EPS:
-0.5492
Flusso di cassa netto:
$-10.52M
1 W Prestazione:
+2.64%
1M Prestazione:
-23.21%
6M Prestazione:
-66.97%
1 anno Prestazione:
-86.90%
Intervallo 1D:
$0.6121
$0.6455
Intervallo di 1 settimana:
$0.5833
$0.6797
Portata 52W:
$0.5833
$5.62
Fibrobiologics Inc Stock (FBLG) Company Profile
Nome
Fibrobiologics Inc
Settore
Industria
Telefono
281-671-5150
Indirizzo
455 E. MEDICAL CENTER BLVD, HOUSTON
Confronta FBLG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.62 | 23.74M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.17 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.75 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.01 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.23 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
253.00 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-24 | Iniziato | Maxim Group | Buy |
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Fall River Herald News
FibroBiologics to Present at the Advanced Wound Care Summit USA - GlobeNewswire
FibroBiologics Reveals Breakthrough Diabetic Foot Ulcer Treatment Ahead of Phase 1/2 Trial - Stock Titan
FibroBiologics Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Fibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell Bank - MarketScreener
FibroBiologics announces advancement in its cartilage repair program - TipRanks
FibroBiologics Confirms Ability to Manufacture CybroCell™ - GlobeNewswire
Breakthrough: FibroBiologics Achieves Major Cost-Saving Milestone in Degenerative Disc Disease Treatment Development - Stock Titan
FibroBiologics Webinar: A Crossroads for Pipeline Progress and IP Dominance in Cell Therapy - AInvest
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform - Nasdaq
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 - GlobeNewswire
FibroBiologics to Reveal Next-Gen Cell Therapy Platform: 275+ Patents Target Billion-Dollar Markets - Stock Titan
Disruptive Innovation and Clinical Breakthroughs: Fathom Holdings and FibroBiologics Lead the Charge - AInvest
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Worcester Telegram
FibroBiologics, Inc.(NasdaqCM: FBLG) dropped from Russell 2000 Index - MarketScreener
FibroBiologics Inc (NASDAQ: FBLG) Has Great Upside Potential - Stocksregister
Fibrobiologics closes third $5 mln tranche of $25 mln financing - MarketScreener
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Raises $25M to Launch Breakthrough Diabetic Foot Ulcer Treatment Trial - Stock Titan
FibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025 - Nasdaq
FibroBiologics to Present at the BIO International Convention 2025 - GlobeNewswire
Clinical Trial Alert: FibroBiologics Unveils Groundbreaking Fibroblast Treatment for Chronic Disease at BIO 2025 - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
FibroBiologics names new CFO after going public last year - The Business Journals
FibroBiologics appoints new CFO amid clinical trials By Investing.com - Investing.com South Africa
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer, Effective June 9, 2025 - MarketScreener
FibroBiologics appoints Jason Davis as CFO - TipRanks
FibroBiologics Appoints Jason Davis As CFO - Nasdaq
FibroBiologics appoints new CFO amid clinical trials - Investing.com Australia
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer to Drive Growth and Clinical Development - Nasdaq
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer - GlobeNewswire
FibroBiologics Taps Former Virax IPO Leader as CFO Ahead of Critical Clinical Trials - Stock Titan
Jane Street Group LLC Acquires 49,222 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Top Executive Makes Bold Move with Major Stock Purchase in FibroBiologics! - TipRanks
FibroBiologics, Inc. (NASDAQ:FBLG) Receives $13.00 Consensus PT from Analysts - Defense World
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis - Research Tree
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis… - Zacks Small Cap Research
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting - GlobeNewswire
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting - Nasdaq
Revolutionary Fibroblast Treatment Shows Promise for Long-lasting Psoriasis Relief, New Data Reveals - Stock Titan
Raymond James Financial Inc. Takes $37,000 Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
FibroBiologics, Inc. Reports First Quarter 2025 Financial Results and Operational Milestones - Nasdaq
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Earnings: Net Loss Drops 41%, Clinical Trial Launch Set for Breakthrough Wound Treatment - Stock Titan
FibroBiologics, Inc. SEC 10-Q Report - TradingView
FibroBiologics (FBLG) Projected to Post Earnings on Tuesday - Defense World
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.
Fibrobiologics Inc Azioni (FBLG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrobiologics Inc Azioni (FBLG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | Chief Executive Officer |
Aug 12 '24 |
Buy |
1.91 |
8,500 |
16,269 |
6,056,647 |
| Khoja Hamid | Chief Scientific Officer |
Aug 12 '24 |
Buy |
1.90 |
10,000 |
19,000 |
11,250 |
0.05%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):